This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.
Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed
by Zacks Equity Research
Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.
Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
Will USTR's 25% Tariff Exemption Spell Relief for MedTech?
by Urmimala Biswas
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
Stryker (SYK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.
Zacks.com featured highlights include: Stryker, T. Rowe, Applied Materials, Fiat and Northrop
by Zacks Equity Research
Zacks.com featured highlights include: Stryker, T. Rowe, Applied Materials, Fiat and Northrop
Why Stryker (SYK) Could Beat Earnings Estimates Again
by Zacks Equity Research
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
5 ROE Stocks to Profit as Fed-Fueled Rate Cut Hopes Soar
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies (PDCO) expects to gain from the Animal Health unit in fourth-quarter fiscal 2019.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
Top Stock Reports for Intel, Altria & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Altria (MO) and Stryker (SYK).
What's in the Offing for HEXO Corp's (HEXO) Q3 Earnings?
by Zacks Equity Research
HEXO Corp's (HEXO) recent 1,000,000 sq. ft. greenhouse expansion is likely to reflect on quarterly results.
Can Segmental Growth Aid Cooper Companies' (COO) Q2 Earnings?
by Zacks Equity Research
Cooper (COO) expects to gain from CVI and CSI units in the fiscal second quarter.
Veeva Systems (VEEV) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Top-line growth and solid show by Subscription services and Professional services units are likely to aid Veeva Systems (VEEV) in Q1 earnings. However, rising expenses remains a dampener.
Stryker (SYK) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra LifeSciences Rides on Product Launch, Faces Rivalry
by Zacks Equity Research
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
Medtronic to Acquire Titan Spine for Spine Portfolio Boost
by Zacks Equity Research
According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
by Zacks Equity Research
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Medtronic's (MDT) EV ICD Pilot Study Results Encourage
by Zacks Equity Research
The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.
Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fall year over year in Q1.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) has been gaining investor confidence on robust performance.